Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Xenin‐25 is a 25 amino acid peptide hormone co‐secreted from the same enteroendocrine K‐cell as the incretin peptide glucose‐dependent insulinotropic polypeptide (GIP). There is no known specific receptor for xenin‐25, but studies suggest that at least some biological actions may be mediated through interaction with the neurotensin receptor. Original investigation into the physiological significance of xenin‐25 focussed on effects related to gastrointestinal transit and satiety. However, xenin‐25 has been demonstrated in pancreatic islets and recently shown to possess actions in relation to the regulation of insulin and glucagon secretion, as well as promoting beta‐cell survival. Accordingly, the beneficial impact of xenin‐25, and related analogues, has been assessed in animal models of diabetes‐obesity. In addition, studies have demonstrated that metabolically active fragment peptides of xenin‐25, particularly xenin‐8, possess independent therapeutic promise for diabetes, as well as serving as bioactive components for the generation of multi‐acting hybrid peptides with antidiabetic potential. This review will focus on continuing developments with xenin compounds in relation to new therapeutic approaches for diabetes‐obesity.
LanguageEnglish
Pagese3006
Number of pages5
JournalDiabetes Metabolism Research and Reviews
Volumee3006
Early online date6 Apr 2018
DOIs
Publication statusE-pub ahead of print - 6 Apr 2018

Fingerprint

Obesity
Peptides
Therapeutics
Neurotensin Receptors
Enteroendocrine Cells
Gastric Inhibitory Polypeptide
Gastrointestinal Transit
Incretins
Peptide Fragments
Peptide Hormones
xenin 25
Glucagon
Islets of Langerhans
Hypoglycemic Agents
Cell Survival
Animal Models
Insulin
Amino Acids

Keywords

  • Xenin-25
  • glucose-dependent insulinotropic polypeptide (GIP)
  • insulin secretion
  • satiety
  • diabetes

Cite this

@article{90d65dbacea2459b80e461229df8535b,
title = "Emerging therapeutic potential for xenin and related peptides in obesity and diabetes",
abstract = "Xenin‐25 is a 25 amino acid peptide hormone co‐secreted from the same enteroendocrine K‐cell as the incretin peptide glucose‐dependent insulinotropic polypeptide (GIP). There is no known specific receptor for xenin‐25, but studies suggest that at least some biological actions may be mediated through interaction with the neurotensin receptor. Original investigation into the physiological significance of xenin‐25 focussed on effects related to gastrointestinal transit and satiety. However, xenin‐25 has been demonstrated in pancreatic islets and recently shown to possess actions in relation to the regulation of insulin and glucagon secretion, as well as promoting beta‐cell survival. Accordingly, the beneficial impact of xenin‐25, and related analogues, has been assessed in animal models of diabetes‐obesity. In addition, studies have demonstrated that metabolically active fragment peptides of xenin‐25, particularly xenin‐8, possess independent therapeutic promise for diabetes, as well as serving as bioactive components for the generation of multi‐acting hybrid peptides with antidiabetic potential. This review will focus on continuing developments with xenin compounds in relation to new therapeutic approaches for diabetes‐obesity.",
keywords = "Xenin-25, glucose-dependent insulinotropic polypeptide (GIP), insulin secretion, satiety, diabetes",
author = "SL Craig and Gault, {Victor A} and Nigel Irwin",
year = "2018",
month = "4",
day = "6",
doi = "10.1002/dmrr.3006",
language = "English",
volume = "e3006",
pages = "e3006",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",

}

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes. / Craig, SL; Gault, Victor A; Irwin, Nigel.

In: Diabetes Metabolism Research and Reviews, Vol. e3006, 06.04.2018, p. e3006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

AU - Craig, SL

AU - Gault, Victor A

AU - Irwin, Nigel

PY - 2018/4/6

Y1 - 2018/4/6

N2 - Xenin‐25 is a 25 amino acid peptide hormone co‐secreted from the same enteroendocrine K‐cell as the incretin peptide glucose‐dependent insulinotropic polypeptide (GIP). There is no known specific receptor for xenin‐25, but studies suggest that at least some biological actions may be mediated through interaction with the neurotensin receptor. Original investigation into the physiological significance of xenin‐25 focussed on effects related to gastrointestinal transit and satiety. However, xenin‐25 has been demonstrated in pancreatic islets and recently shown to possess actions in relation to the regulation of insulin and glucagon secretion, as well as promoting beta‐cell survival. Accordingly, the beneficial impact of xenin‐25, and related analogues, has been assessed in animal models of diabetes‐obesity. In addition, studies have demonstrated that metabolically active fragment peptides of xenin‐25, particularly xenin‐8, possess independent therapeutic promise for diabetes, as well as serving as bioactive components for the generation of multi‐acting hybrid peptides with antidiabetic potential. This review will focus on continuing developments with xenin compounds in relation to new therapeutic approaches for diabetes‐obesity.

AB - Xenin‐25 is a 25 amino acid peptide hormone co‐secreted from the same enteroendocrine K‐cell as the incretin peptide glucose‐dependent insulinotropic polypeptide (GIP). There is no known specific receptor for xenin‐25, but studies suggest that at least some biological actions may be mediated through interaction with the neurotensin receptor. Original investigation into the physiological significance of xenin‐25 focussed on effects related to gastrointestinal transit and satiety. However, xenin‐25 has been demonstrated in pancreatic islets and recently shown to possess actions in relation to the regulation of insulin and glucagon secretion, as well as promoting beta‐cell survival. Accordingly, the beneficial impact of xenin‐25, and related analogues, has been assessed in animal models of diabetes‐obesity. In addition, studies have demonstrated that metabolically active fragment peptides of xenin‐25, particularly xenin‐8, possess independent therapeutic promise for diabetes, as well as serving as bioactive components for the generation of multi‐acting hybrid peptides with antidiabetic potential. This review will focus on continuing developments with xenin compounds in relation to new therapeutic approaches for diabetes‐obesity.

KW - Xenin-25

KW - glucose-dependent insulinotropic polypeptide (GIP)

KW - insulin secretion

KW - satiety

KW - diabetes

U2 - 10.1002/dmrr.3006

DO - 10.1002/dmrr.3006

M3 - Article

VL - e3006

SP - e3006

JO - Diabetes/Metabolism Research and Reviews

T2 - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

ER -